Spero's Q2 Loss Widens, but $105M Royalty Financing Extends Runway to 2029

summarizeSummary

Spero Therapeutics reported a Q2 net loss of $9.6 million with zero revenue, but its cash runway extends into 2029 following a $105 million royalty financing. The company is pivoting to SP001 development after FDA approval of Utebzi.

check_boxKey Events · Earnings and Guidance · SPRO

• Q2 Net Loss Widens

  Net loss of $9.6 million for Q2 2026, up from $1.7 million in Q2 2025, with total revenue falling to zero from $14.2 million.

• Cash Runway Extended to 2029

  Cash and cash equivalents of $50.8 million as of June 30, 2026, combined with $105 million royalty financing closed July 8, 2026, funds operations into the second half of 2029.

• Royalty Financing Terms

  Sold 65% of future GSK Proceeds after note repayment to HCRx for $105 million in senior secured notes; retains 35% of GSK Proceeds.

• SP001 License Costs

  Paid $35 million upfront to Innovent for SP001 license, with up to $1.05 billion in potential milestone payments.

auto_awesomeAnalysis · SPRO · Life Sciences

The second quarter brought a wider net loss of $9.6 million, up from $1.7 million a year earlier, as revenue fell to zero with collaboration and grant income drying up. A cash position of $50.8 million, combined with the $105 million royalty financing closed in July, extends the runway into the second half of 2029. The 10-Q also details the $35 million upfront payment for the SP001 license from Innovent, termination of the BARDA contract, and termination of the Everest Medicines agreement. Going forward, the company's prospects hinge on SP001 development and GSK's commercialization of Utebzi, with only 35% of GSK proceeds retained after the royalty financing.